Inherited bone marrow failure syndromes (IBMFS) are caused by mutations in genes involved in genomic stability. Although they may be recognized by the association of typical clinical features, variable penetrance and expressivity are common, and clinical diagnosis is often challenging. DNAJC21, which is involved in ribosome biogenesis, was recently linked to bone marrow failure. However, the specific phenotype and natural history remain to be defined. We correlate molecular data, phenotype, and clinical history of 5 unreported affected children and all individuals reported in the literature. All patients present features consistent with IBMFS: bone marrow failure, growth retardation, failure to thrive, developmental delay, recurrent infections, and skin, teeth or hair abnormalities. Additional features present in some individuals include retinal abnormalities, pancreatic insufficiency, liver cirrhosis, skeletal abnormalities, congenital hip dysplasia, joint hypermobility, and cryptorchidism. We suggest that DNAJC21-related diseases constitute a distinct IBMFS, with features overlapping Shwachman-Diamond syndrome and Dyskeratosis congenita, and additional characteristics that are specific to DNAJC21 mutations.
The full phenotypic spectrum, natural history, and optimal management will require more reports. Considering the aplastic anemia, the possible increased risk for leukemia, and the multisystemic features, we provide a checklist for clinical evaluation at diagnosis and regular follow-up.
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| PATIENTS AND METHODS
We describe 5 previously unreported children from 2 families of the same Canadian First-Nation origin, as well as updated clinical information on 3 affected individuals from 2 previously reported families. 2, 4 All patients were evaluated in a clinical setting by multiple specialists, including a geneticist. Approval for genomic studies was obtained from the Research Ethics Board of the CHU Sainte-Justine, and informed consent to publication of clinical information and photographs was obtained from parents or guardians.
| RESULTS
Molecular data and clinical information are summarized in Table 1 and detailed in Table S1 , Supporting Information. Pedigrees are available in Figure S1 Available parents were heterozygous ( Figure S1 in File S3).
The identified mutation, NM_001012339.2:c.100A > G:p.Lys34-Glu, deemed probably pathogenic (PM2, PM1, PP3, PP1), 5 has since been reported in 2 siblings from a Canadian First-Nation tribe. 3 Including the patients in the current report, a total of 15 individuals carrying 9 different mutations, are now described with clinical information (summary in Table 1 , details in Table S1 ). This includes 
| Current report
We report the largest group of children with the same biallelic mutation in DNAJC21. They presented cytopenia(s), postnatal growth delay, failure to thrive (File S1 This contrasts with Tummala's report, where all individuals had normal telomere length. 2 This discrepancy could be the result of the measurement method used, 6,7 disease severity, or each mutation's pathogenic mechanism. Although telomere shortening has been described in other non-DC IBMFS, such as SDS and FA, 8 it remained above the 1st percentile for most patients with SDS (12/14). In contrast, all patients tested in our cohort had at least one subpopulation at or below the 1st percentile, with most between 1st and 10th percentile, which is consistent with some level of telomere maintenance defect. Indeed, previous reports showed that defining normal telomere length as above the 1st percentile would miss children with telomeropathies, 9 considering that up to one in 7 are in the 1st to 10th percentile range. 8 In contrast to Dhanraj's report, 3 although 2 individuals in our cohort had pancreatic hyperechogenicity (Patients 1 and 2), none showed clear evidence of pancreatic insufficiency (Table S1 ). Both had mild liver enzymes elevation, one developed cirrhosis by age 11, which is not typical of SDS. The siblings from Dhanraj's report carrying the same mutation also had signs of liver disease, suggesting an association with this specific mutation. (Table 2 ).
| Natural history
All children in our cohort showed various degree of bone marrow failure, but none of them required bone marrow transplant (BMT) nor developed leukemia (details in File S2). Moreover, although our cohort is small, all patients followed at our center showed improvement in their cell counts with age, except for lymphocytes ( Figure S5 and the significance of this cytogenetic abnormality remains unknown (details in File S2). This deletion may represent an initial event that could lead to tumorigenesis, or a rescue mechanism that could help recover hematopoiesis, or both.
We report updated clinical information on 3 previously reported patients (details in Table S1 , pedigrees in Figure S1 in File S3). To our knowledge, only one individual with a DNAJC21 mutation developed leukemia (Patient 6). He died from transplant-related morbidity, after a mismatched BMT for acute megakaryoblastic leukemia. Another 2-year-old male (Patient 8) is currently stable and no longer transfusion-dependent, 9 months after an uncomplicated matched BMT performed for severe pancytopenia (details in Table S1 ). His sister (Patient 7) required transfusions in infancy, but her counts have stabilized since. Two siblings reported by Dhanraj died: one from sepsis, and one from EBV-associated lymphoproliferative disorder shortly after BMT. Neither had leukemia, but one had a bone marrow karyotype abnormality: der(15)t(1;15)(q12;p11).
Biallelic mutations in DNAJC21 cause a distinct IBMFS, with some clinical overlap with SDS and DC, and additional features such as retinal abnormalities, liver cirrhosis, congenital hip dysplasia, joint hypermobility, and cryptorchidism. More reports are needed to understand the full phenotypic spectrum and long-term evolution of affected individuals, and establish optimal management, including BMT indications and protocol. Aplastic anemia, and a possible increased risk for leukemia warrants regular hematological follow-up, and multidisciplinary care to address all other potential medical issues.
